Karen M Chisholm
Overview
Explore the profile of Karen M Chisholm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
940
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamdan H, Liu Y, Wang S, Bledsoe J, Chisholm K, Siddon A, et al.
EJHaem
. 2025 Jan;
6(1):e1052.
PMID: 39866946
Background: Acute myeloid leukemia (AML) with RAM immunophenotype is a newly recognized high-risk AML immunophenotypic subcategory characterized by blasts with bright expression of CD56 and weak to absent expression of...
2.
Alnoor F, Rangel A, Luo M, Silva O, Chisholm K, OMalley D, et al.
Int J Lab Hematol
. 2024 Nov;
47(1):26-35.
PMID: 39501556
Castleman Disease (CD) is a rare lymphoproliferative disorder that can be separated into two primary forms: Unicentric Castleman disease (UCD) and multicentric Castleman disease (MCD). UCD is localized, while MCD...
3.
Silbert S, Scanlon S, Wang H, Yuan C, Doverte A, Wellek J, et al.
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39461880
Lineage switch (LS) refers to the immunophenotypic transformation of one leukemia lineage to another (ie, lymphoid to myeloid) with retention of baseline genetics. This phenomenon was originally observed in infants...
4.
Das M, Tsuchiya K, Bohling S, Davis B, Hwang S, Gardner R, et al.
Pediatr Dev Pathol
. 2023 Nov;
27(2):193-197.
PMID: 38032739
B-lymphoblastic leukemia/lymphoma (B-ALL/LBL) is a precursor B-cell neoplasm that often harbors specific cytogenetic/molecular abnormalities with distinctive clinical, phenotypic, and prognostic characteristics. Subcategorization of B-ALL/LBL therefore requires extensive cytogenetic and/or molecular...
5.
Chisholm K, Bohling S
Clin Lab Med
. 2023 Oct;
43(4):639-655.
PMID: 37865508
Myelodysplastic syndrome (MDS) in children is rare, accounting for < 5% of all childhood hematologic malignancies. With the advent of next-generation sequencing, the etiology of many childhood MDS (cMDS) cases...
6.
Small C, Mukerjee S, Jangam D, Gollapudi S, Singh K, Jaye D, et al.
Int J Lab Hematol
. 2023 Jun;
45(5):726-734.
PMID: 37282364
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematopoietic disease derived from plasmacytoid dendritic lineage cells. The disease typically shows skin as well as frequent bone marrow and...
7.
Comprehensive molecular and clinical characterization of fusions in pediatric acute myeloid leukemia
Bertrums E, Smith J, Harmon L, Ries R, Wang Y, Alonzo T, et al.
Haematologica
. 2023 Feb;
108(8):2044-2058.
PMID: 36815378
NUP98 fusions comprise a family of rare recurrent alterations in AML, associated with adverse outcomes. In order to define the underlying biology and clinical implications of this family of fusions,...
8.
Chisholm K, Smith J, Heerema-McKenney A, Choi J, Ries R, Hirsch B, et al.
Pediatr Blood Cancer
. 2023 Feb;
70(5):e30251.
PMID: 36789545
Background: Acute myeloid leukemia (AML) with megakaryocytic differentiation (AMkL) is a rare subtype of AML more common in children. Recent literature has identified multiple fusions associated with this type of...
9.
Lee B, Summers C, Chisholm K, Bohling S, Leger K, Gardner R, et al.
Blood Adv
. 2023 Feb;
7(12):2825-2830.
PMID: 36763522
No abstract available.
10.
Afify Z, Taj M, Orjuela-Grimm M, Srivatsa K, Miller T, Edington H, et al.
Cancer
. 2022 Dec;
129(5):780-789.
PMID: 36571557
Background: Pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorder [EBV(-)M-PTLD] comprises approximately 10% of M-PTLD. No large multi-institutional pediatric-specific reports on treatment and outcome are available. Methods: A...